Constitutive Activation of the JAK/STAT and Toll-Like Receptor Signaling Pathways in Adult T-Cell Leukemia/Lymphoma

Takehiro Higashi, Takefumi Katsuragi, Atsushi Iwashige, Hiroaki Morimoto and Junichi Tsukada
Cancer Chemotherapy Center and Hematology
University of Occupational and Environmental Health, Kitakyushu
Japan

1. Introduction

Adult T-cell leukemia/lymphoma (ATLL) caused by the retrovirus human T-cell leukemia virus type 1 (HTLV-1) infection is one of aggressive mature CD4+ T-cell neoplasms with a marked expansion of leukemic cells during the acute phase. ATLL is endemic in several regions of the world, especially in southwest Japan, the Caribbean basin, and parts of Central Africa. ATLL is divided into four clinical subtypes: acute, chronic, smoldering, and lymphoma type, based on the number of leukemic cells in peripheral blood, serum lactic acid dehydrogenase level, tumor lesions in various organs, and clinical course. The acute and lymphoma types still have an extremely poor prognosis, despite the advance in chemotherapy. Chemotherapy for ATLL has limited efficacy with median survivals of approximate one year.

The HTLV-1 genome encodes not only structural proteins, but also non-structural proteins such as Tax, Rex, p13, p12, p30, p21Rex and HTLV-1 bZIP factor (HBZ). The functional analysis of the viral proteins such as Tax has shed light on the pathogenesis of ATLL. Tax is a crucial viral protein encoded by the pX region, which can induce viral replication and a variety of cellular genes associated with cytokine production, inhibition of apoptosis and cell cycle dysregulation (Arima 1999, Azimi 1998, Geleziunas 1998, Kanno 1994, Mori 1996b). Tax-induced gene regulation, which is linked to malignant transformation of HTLV-1-infected T-cells, has been shown to be mediated by CREB/ATF, NF-κB and SRF pathways. Constitutive activation of NF-κB is one of common features of HTLV-1-transformed T-cells and ATLL leukemic cells, since inhibition of NF-κB activity reduces cell growth and induces apoptosis of cells, suggesting a central role of NF-κB in their proliferation and survival. Moreover, Tax binds to the upstream kinase, the mitogen-activated protein kinase/ERK kinase kinase-1 and enhance its kinase activity (Harhaj 1999, Huang 2002, Jin 1999). Nevertheless, ATLL develops in a period 40 to 60 years after initial infection, indicating that the development of ATLL requires a multistep oncogenic process including accumulation of genetic mutations. HTLV-1 infection alone is not sufficient to induce neoplastic transformation of infected cells. In fact, viral gene expression is at extremely low levels in primary ATLL cells (Franchini 1984). Thus, the mechanism which develops ATLL still remains unclear.
The general subject of signaling pathways in ATLL cells and HTLV-1-transformed cells has been covered by many excellent original reports and reviews. In this review, authors focus on recent advances of two signaling pathways in ATLL cells and HTLV-1-transformed T-cells; the JAK (Janus kinase)-STAT (signal transducer and activator of transcription) and TLR (Toll-like receptor) signaling pathways.

2. Constitutive activation of the JAK-STAT signaling pathway in ATLL cells and HTLV-1-transformed T-cells

STAT proteins play important roles in regulating cellular response to a variety of cytokines. STATs are latent cytosolic transcriptional factors that are activated by tyrosine phosphorylation in response to cytokines. The four mammalian members of the JAK family (Jak1, Jak2, Jak3, and Tyk2) are non-receptor tyrosine kinases functioning as signal transducers, that control activation of STATs. Jaks associate constitutively with cytokine receptors, and promote signals by phosphorylating tyrosine residues of activated receptors to allow the recruitment and activation of STAT proteins. STATs can form homo- or heterodimers in which amino acid sequence containing a phospho-tyrosine residue in one partner binds to the SH2 domain in the other vice versa, leading to nuclear translocation of STAT dimers and their participation in transcriptional regulation of various cytokine responsive genes (Darnell 1997, Ihle 2001, Leonard 1998).

![Diagram of the JAK-STAT signaling pathway in ATLL cells and HTLV-1-transformed T-cells.](https://www.intechopen.com)

Fig. 1. The JAK-STAT signaling pathway in ATLL cells and HTLV-1-transformed T-cells.
Recent reports have emphasized the significance of STATs in oncogenesis (Akira 1997) and leukemogenesis (Bowman 2000, Lin 2000, Levy 2000, Coffer 2000, Akira 1997). Many oncoproteins can activate STATs. In contrast to the normal cellular response, which shows rapid and transient activation of STATs, aberrant activation of JAK-STAT signaling contributes to malignant transformation. The v-abl oncogene of the Abelson murine leukemia virus (A-MuLV) induces JAK-STAT signaling, involving Jak1 and Jak3 (Danial 1995). Interestingly, constitutive expression of a dominant-active STAT3 induces neoplastic transformation (Bromberg 1999). STAT1 and STAT5 are active in BCR-ABL-positive leukemias (Carlesso 1996, Shuai 1996, Frank 1996) and STAT1, STAT3 and STAT5 are constitutively activated in acute leukemia blasts (Gouilleux-Gruart 1996, Weber-Nordt 1996, Xia 1998, Spiekermann 2001). A constitutively active form of STAT3 can transform cells (Bromberg 1999). Constitutive activation of Jaks and STATs has been observed in murine pre-B lymphocytes transformed with the A-MuLV (Danial 1995), human B cells transformed with Epstein-Barr virus (Gouilleux-Gruart 1996) and murine erythroleukemia induced by spleen focus-forming virus (Ohashi 1995). Primary acute leukemia cells also show constitutive activation of STATs (Gouilleux-Gruart 1996, Weber-Nordt 1996, Xia 1998, Spiekermann 2001). Moreover, constitutive STAT3 activation in acute myeloid leukemia blasts has been reported to be associated with short disease-free survival, showing a prognostic significance for STAT3 (Benekli 2002).

HTLV-1 infects and immortalizes primary human T-cells. In early stage, the viral regulatory proteins Tax and Rex are involved in the up-regulation of IL-2 and IL-2R. In some ATL cases, IL-2 and IL-15 can induce growth of ATLL cells (Arima 1996, Maeda 1987, Yamada 1998) (Fig. 1). Phosphorylation of STAT3 and STAT5 in ATL cells is induced by IL-2, IL-15 and IL-21 (Ueda 2005). A paracrine growth loop that involves Tax-induced IL-9 production in ATL cells and expression of IL-9 receptor α on monocytes has been also observed (Chen 2008). However, constitutive activation of the JAK-STAT pathway is generally correlated with IL-2 independence. Transformation of T-cells by HTLV-1 is associated with constitutive activation of the JAK-STAT pathway (Migone 1995, Xu 1995) (Fig1). Migone et al. (Migone 1995) demonstrated activation of Jak1, Jak3, STAT3 and STAT5 correlated with the transition from an IL-2-dependent to an IL-2-independent phase in HTLV-1-transformed cells. Spontaneous phosphorylation of Jak2 and Jak3 has also been observed in T-cells transformed with HTLV-1 (Xu 1995). Leukemia cells obtained from ATL patients also showed constitutive activation of STATs (Takemoto 1997, Tsukada 2000). Takemoto et al. (Takemoto 1997) observed constitutive activation of STAT1, STAT3 and STAT5 in leukemic cells of ATL patients, and demonstrated the association of leukemic cell proliferation with constitutive JAK-STAT activity.

In addition, no gain-of-function mutations of the Jak1 and Jak3 in primary ATLL cells has been detected (Kameda 2010). These data are contrast to the results obtained from acute T-lymphoblastic leukemia (T-ALL). Flex et al. demonstrated that JAK1 gene mutations occur in ALL and are more frequently observed among adult individuals with involvement of the T cell lineage (Flex 2008). The mutations promote gain of kinase function, and are associated with poor response to therapy and overall prognosis.

2.1 Unique function of the Jak-STAT signaling pathway in HTLV-1-infected T-cells

HTLV-1 infection up-regulates expression of the suppressor of cytokine signaling 1 (SOCS1). HTLV-1-induced SOCS1 inhibits the type I IFN antiviral response against HTLV-1 by
targeting IRF3 for SOCS1-induced proteasome degradation (Oliere 2010). As an adaptor, SOCS1 brings target proteins to the elongin B/C-Cullin E3 ligase complex for ubiquitination. It may represent an immune evasion strategy and survival advantage to HTLV-1-infected cells. HTLV-1 inhibits IFNα-induced phosphorylation of STAT2 and Tyk2 (Feng 2008). Zhang et al. further indicate that Tax interferes with IFN-α-induced JAK-STAT signaling by completion with STAT2 for CBP/p300 binding (Zhang 2008) (Fig2).

Fig. 2. Constitutive association of MyD88 with IRAK in HTLV-1-transformed T-cells.

The viral p12 protein from the pX open reading frame I (ORFI) activates Jak1/3 and STAT5, and decrease the IL-2requirement for T-cell proliferation via binding to the cytoplasmic domain of IL-2Rβ chain (Nicot 2001). Although the IL-2-Jak-STAT pathway is not associated with viral gene expression, viral RNA encapsidation, the maturation of the viral particle, cell-cell adherence or Gag polarization, p12 enhances viral transmission through activation of the IL-2-Jak-STAT pathway (Taylor 2009).

2.1.1 Inhibition of the JAK-STAT signaling pathway in ATLL cells and HTLV-1-transformed T-cells; therapeutic approach

Several recent studies reported inhibition of constitutive activation of the JAK-STAT signaling pathway in ATLL cells and HTLV-1-transformed T-cells. Src-related kinase Lyn...
co-immunoprecipitates with Jak3 in HTLV-1-transformed cell lines HUT102, MT2, MS9 and MS68. Phosphorylation of STAT5 and STAT3 are inhibited by cell treatment with the Src kinase inhibitor PP2 or by ectopic expression of a dominant negative Lyn kinase protein (Shuh 2011). Dequelin, a naturally occurring retinoid shows anti-proliferative effect on HTLV-1-transformed cells, MT-2 and KUT-1 in part through the down-regulation of survivin and constitutive phosphorylation of STAT3. In contrast, STAT5 phosphorylation is not affected by Deguelin (Ito 2010). Roscovitine, an inhibitor of cyclin-dependent kinases (CDKs) inhibits STAT5 activity required for the survival of MT-2 cells. A dominant negative STAT5 expression induces apoptosis and reduces the abundance of an anti-apoptotic protein XIAP in MT-2 cells. In ChIP assay, interaction of STAT5, but not STAT1 with the XIAP promoter has been observed. Interaction of STAT5 and PDGFα receptor is also prevented by roscovitine (Mohapatra 2003). Curcumin (diferuloylmethane), a naturally occurring yellow pigment isolated from the rhizomes of the plant Curcuma longa, induces apoptosis and anti-proliferative response in HTLV-1-transformed cells; MT-2, HUT102 and SLB-1. These responses are associated with inhibition of constitutive phosphorylation of Jak3, Tyk2, STAT3 and STAT5. Additionally, AP-1, especially JunD and NF-κB activity in HTLV-1-transformed T-cells and primary ATLL cells are also inhibited by curcumin (Tomita 2006a, Tomita 2006b).

In a clinical study, Berkowitz et al. reported a single institute open-label phase II trial of intravenous daclizumab, a humanized monoclonal antibody that binds specifically to the alpha (CD25) subunit of the high-affinity IL-2R in ATLL patients. No responses were observed in aggressive acute or lymphoma type of ATLL. Partial responses were observed in 36% of patients with chronic and smoldering ATLL (Berkowitz JL 2010).

In addition, Tasocitinib (CP-690,550), a potent and selective Jak3 inhibitor is an orally active immunosuppressant undergoing clinical trials for the treatment of autoimmune diseases and transplant rejection. It is interesting to note that Tasocitinib (CP-690,550) inhibits proliferation of peripheral blood mononuclear cells (PBMCs) from patients with chronic and smoldering form of ATLL or with HAM/TSP that manifest constitutive Jak3/STAT5 activation. This agent prolongs the survival of transgenic mice bearing human CD8 T-cell leukemia with IL-15/IL-15R autocrine growth loop required for leukemia cell survival (Ju 2011). These results suggest clinical effect of CP-690,550 on chronic and smoldering ATLL.

### 2.1.2 Constitutive tyrosine and serine phosphorylation of STAT4 in T-cells transformed with HTLV-1

STAT4 is a crucial mediator of IL-12-stimulated gene regulation (Jacobson 1995, Bacon 1995b). In fact, the development of type-1 helper T (Th1) cells and production of IFN-γ in response to IL-12 are disrupted in STAT4-deficient mice (Thierfelder 1996, Kaplan 1996). STAT4 is phosphorylated on tyrosine by Jak2 and Tyk2 (Bacon 1995a, Cho 1996). Moreover, IL-12 activates the p38/MKK6 signaling pathway that in turn phosphorylates STAT4 on serine (Visconti 2000). Activation of p38 and its upstream activator MKK6 is an important step for IL-12-induced STAT4 transcriptional activity (Visconti 2000, Zhang 2000). In fact, previous studies indicated that IFN-γ production is blocked by a p38 inhibitor (Zhang 2000, Rincon 1998). Transgenic mice expressing a dominant-negative p38 showed impaired Th1 differentiation (Rincon 1998). The expression of STAT4 is observed in limited types of tissues such as testis, spleen, lung, bone marrow, thymus and muscle (Zhong 1994, Yamamoto 1994). Several T-cell lines including EL4 and DA2 contain no
STAT4 transcripts (Yamamoto 1994). However, our study showed that tyrosine-phosphorylated STAT4 was detected in HTLV-1-transformed cell lines. In addition, STAT4 protein was constitutively phosphorylated on serine as well as on tyrosine in HTLV-1-transformed cell lines (Higashi 2005).

The relevance of phosphorylation of serine in STAT4 has been recently reported. Serine phosphorylation of STAT4 is dispensable for nuclear translocation or DNA binding of STAT4, but is indispensable for its maximal transcriptional activity (Visconti 2000). Serine phosphorylation of STAT4 is required for IL-12-induced IFN-γ production and IL-12-mediated Th1 development, but not for IL-12-induced cell proliferation (Morinobu 2002). Furthermore, they have shown that serine phosphorylation of STAT4 is partially dependent on precedent tyrosine phosphorylation of STAT4, whereas tyrosine phosphorylation of STAT4 can be seen even in the absence of serine phosphorylation. In contrast, it has been shown that in leukemic cells from chronic lymphocytic leukemia patients, STAT1 and STAT3 are constitutively phosphorylated on serine, but not on tyrosine residue (Frank 1997). In the other leukemias such as AML and ALL, serine phosphorylation of the STATs was occasionally seen (Frank 1997, Hayakawa 1998). Thus, STATs may have selective effects on gene expression of leukemia cells in a manner dependent upon serine phosphorylation. We observed that IFN-γ, but not IL-12 or IFN-α was produced in HTLV-1-transformed cells.

2.1.3 Constitutive association of MyD88 to IRAK in HTLV-1-transformed cells

Aberrant cytokine gene expression is a hallmark of ATLL cells (Franchini 1995, Grossman 1997, Kanno 1994, Mori 1999, Mori 1996a, Mori 1996b, Siekevitz 1987, Yamada 1996). The cytokine gene promoters possess enhancer elements for NF-κB and/or C/EBPβ (NF-IL6) (Azimi 1998, Faggioli 1996, Mercurio 1997, Perkins 1997, Schmitz 1995, Washizu 1998). C/EBPβ (NF-IL6), β isoform of CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors (Tsukada 2011) was originally identified as a nuclear factor that binds to IL-1-responsive element in the IL6 gene (Akira 1990). Moreover, inhibition of NF-κB activity results in enhanced apoptosis and growth suppression of primary ATLL cells and HTLV-1-transformed T-cells, indicating a central role for NF-κB in their survival and proliferation. Antisense oligonucleotides to RelA/p65 inhibit Tax-transformed tumor cell growth (Kitajima 1992). Sodium salicylate and cyclopentenone prostaglandins suppress proliferation of Tax-transgenic mouse spleen cells (Portis 2001). Bay-7082, an inhibitor of IκB phosphorylation induces apoptosis of HTLV-1-transformed T-cell lines and primary ATLL cells via reduced expression of the anti-apoptotic gene BCL-XL (Mori 2002). Ex vivo treatment of PBMCs with dehydroxymethylepoxyquinomycin selectively purges HTLV-1-infected cells without toxicity to normal cells in HTLV-1 carriers (Watanabe 2005). More recently, activation of the classical pathway of NF-κB by the HBZ has been reported (Zhao 2009). HBZ does not affect the alternative pathway of NF-κB, but induces polyubiquitination and degradation of p65. Yasunaga et al. demonstrated that ubiquitin-specific peptidase USP20 deubiquitinates TRAF6 and Tax and suppresses Tax-induced NF-κB activation (Yasunaga 2011). Several agents such as Bidens pilosa, a plant found in tropical and subtropical regions (Nakama 2011) and hippuristanol, an eukaryotic translation initiation inhibitor from the coral Isis hippuris (Tsumuraya 2011) also show inhibitory effect on ATLL cells through suppression of NF-κB activity. On the other hand, pan-aurora kinase inhibitor has been shown to have anti-proliferative effect on HTLV-1-transformed T-cells and primary ATLL cells through the suppression of NF-κB activity (Tomita 2009). However, the
same study group reported that AZD1152, a selective inhibitor for Aurora B kinase had no effect on NF-κB activity in MT-4 and HUT102 cells (Tomita 2010).

The TLR comprise a subfamily within the larger superfamily of interleukin (IL) receptors, based on similarity within their cytoplasmic regions (Dunne 2003, Matsushima 2007, McGettrick 2007, Takeda 2003) The extracellular region of the IL-1 receptors (IL-1Rs) possesses three immunoglobulin-like domains, those of TLRs are characterized by the presence of 16-28 leucine-rich repeats. Engagement of IL-1R or TLR with their cognate ligands causes an adaptor protein MyD88 to be recruited to the receptor complex, which, in turn, promotes its association with the IL-1R–associated kinase (IRAK) via an interaction between the respective death domains of each molecule. This is followed by auto-phosphorylation of IRAK that results in dissociation from the receptor complex and its subsequent interaction with tumor-necrosis-factor (TNF) receptor–associated factor-6 (TRAF-6). Emanating from TRAF-6, two signaling pathways diverge, one eventually leading to NF-κB activation, and another to mitogen-activated protein (MAP) kinase activation (Takeuchi 2007).

In this regard, our study demonstrated an alternative mechanism of NF-κB activation through the TLR signaling cascade including MyD88 and IRAK in HTLV-1–transformed T-cells and ATLL cells (Fig. 2). MyD88 and IRAK1 are constitutively active in HTLV-1-transformed T-cells, but not in HTLV-1-negative T-cells (Mizobe 2007). MyD88, originally isolated as a myeloid differentiation primary response gene product, possesses its C-terminal domain, which is highly homologous to the cytoplasmic regions of the TLR family of proteins (Dunne 2003, Takeda 2003). However, unlike members of the TLR family, MyD88 contains no transmembrane domain. MyD88 acts as an adapter molecule of most TLRs and receptors for IL-1 and IL-18 to recruit IRAK to the TLR complex, thereby regulating activation of various transcription factors involved in inflammatory responses, such as NF-κB and C/EBPβ (NF-IL6) (Akira 2003a, Akira 2001, Akira 2003b, Boch 2003, Burns 1998, Dunne 2003, Jefferies 2001, Muzio 2000, O’Neill 2003, Takeda 2003).

Expression of a dominant negative MyD88 (MyD88dn) lacking its death domain (DD), MyD88dn induces apoptosis and anti-proliferative response in HTLV-1-transformed T-cells. In HTLV-1-transformed T-cells, MyD88dn protein expression inhibits constitutive activation of C/EBPβ (NF-IL6) and NF-κB, and proinflammatory cytokine gene promoters such as IL-1α, IFN-γ and TNF-α. Furthermore, Tax synergistically activates NF-κB with MyD88 (Mizobe 2007). The synergy may suggest ligand-independent activation of MyD88 in HTLV-1-transformed cells (Fig. 2). However, NF-κB activation has been observed even in ATLL cells lacking detectable Tax expression. The mechanism for activation of NF-κB in ATLL cells is not still clear. A recent study reported contribution of elevated CD30 expression to constitutive activation of NF-κB in ATLL cells (Higuchi 2005). In this regard, the non-canonical pathway for NF-κB activation, induced by B-cell activation factor (Claudio 2002, Kayagaki 2002), lymphotoxin-β (Dejardin 2002, Saitoh 2002), CD40 (Coope 2002), TNF-like weak inducer of apoptosis (Saitoh 2003) or CD30 (Higuchi 2005) may be also involved in constitutive NF-κB activation in ATLL cells (Hironaka 2004).

In addition, MT-2 cells express TLR-1, 6 and 10 mRNA. Several recent reports have indicated unique expression profiles of TLRs on different subsets of T-cells. Gelman et al. (Gelman 2004) reported that TLR-3, -5 and -9 are expressed selectively on activated human CD4+ T cells, and that treatment of activated human CD4+ T-cells, with dsRNA synthetic analogs, poly(I:C) and CpGoligodeoxynucleotides (CpG DNA), directly enhance their
survival without affecting proliferation. A TLR-5 ligand flagellin and a TLR7/8 ligand R-848 promotes proliferation and to upregulate production of IFN-γ, IL-8 and IL-10, but not IL-4, in human CD4+ T-cells (Caron 2005). In particular, engagement of TLR-5 with flagellin enhances the suppressive capacity and FOXP3 expression in Treg cells (Crelin 2005). Direct modulation of Treg function by TLR2 ligands has been also reported (Oberg 2010). On the other hand, IRF-5 (P68) with a mutation of Ala to Pro at amino acid 68 (G202C; position relative to translation start codon) suppresses TLR-mediated IL-6 and IL-12p40 induction. The mutation has been identified in peripheral blood of ATLL patients (Yang 2009).

A more recent report has emphasized the significance of MyD88 in the pathogenesis and therapeutic approach for lymphoma. Ngo et al. identified a single leucine-to-proline substitution at amino acid position 265 of MyD88 protein (L265P) in 29% of activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) biopsy samples. This mutation occurs at an evolutionally invariant residue in the hydrophobic core and is rare or absent in the other DLBCL subtypes. They further demonstrated that in ABC DLBCL with L265P mutation, MyD88 L265P rescued the cell after MyD88 knockdown, but wild-type MyD88 was ineffective, showing that the L265P is a gain-of-function mutation and ABC DLBCL with L265P mutation depends upon the MyD88 signaling pathway. A selective small molecule inhibitor of IRAK1 and IRAK4 killed the ABC DLBCL cells. Moreover, in ABC DLBCL cell lines, MyD88 knockdown diminishes the secretion of IL-6 and IL-10 and phosphorylation of STAT3 (Ngo 2011).

3. Conclusion

Investigations have led to the demonstration of the several regulatory mechanisms presented in this review. Recent reports have provided detailed insight into the crucial functional roles of JAK-STAT and MyD88-TLR in ATLL. An important goal of such approaches would be the identification of unique targets for clinical intervention. The fact that the two signaling pathway are attractive targets for leukemia therapies further argues the importance of constitutive activation of these factors in ATLL cells.

4. References

Akira, S, Isshiki, H, Sugita, T, Tanabe, O, Kinoshita, S, Nishio, Y, Nakajima, T, Hirano, T & Kishimoto, T (1990) A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J, 9, 6, 1897-906, 0261-4189.


Faggioli, L, Costanzo, C, Merola, M, Bianchini, E, Furia, A, Carsana, A & Palmieri, M (1996) Nuclear factor κB (NF-κB), nuclear factor interleukin-6 (NFIL-6 or C/EBPβ) and nuclear factor interleukin-6 β (NFIL6-β or C/EBPβ) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human breast carcinoma cell line. Eur J Biochem, 239, 3, 624-31, 0014-2956.


Constitutive Activation of the JAK/STAT
And Toll-Like Receptor Signaling Pathways in Adult T-Cell Leukemia/Lymphoma


HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PloS Pathog, 6, 11, e1001177, 1553-7374.


The purpose of this book is to provide a comprehensive review of the scientific advances in T-cell malignancies and to highlight the most relevant findings that will help the reader understand both basic mechanisms of the disease and future directions that are likely to lead to novel therapies. In order to assure a thorough approach to these problems, contributors include basic scientists, translational researchers and clinicians who are experts in this field. Thus, the target audience for this book includes both basic scientists who will use this book as a review of the advances in our fundamental knowledge of the molecular mechanisms of T-cell malignancies, as well as clinicians who will use this book as a tool to understand rationales for the development of novel treatments for these diseases.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: